Product Name:
ILK1-pY351
Product Number:
ab-pk662
Target Full Name: Integrin-linked protein-serine kinase-1
Target Alias: 59 kDa serine/threonine protein kinase; ILK1; ILK-1; Integrin-linked kinase; Kinase ILK; P59ILK; ILK2; DKFZp686F1765; P59; CCDS7768.1; ENSG00000166333
Product Type Specific: ILK1 protein kinase phosphosite-specific antibody
Antibody Code: PK662
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y351
Protein UniProt: Q13418
Protein SigNET: ILK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ILK1 sequence peptide Cat. No.: PE-04ABW85
Antibody Immunogen Sequence: GRM(pY)APA(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues G348 to A354; in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y351 phosphorylation stimulates phosphotransferase activity. This phosphosite is located in the kinase activation loop between catalytic subdomains VII and VIII. Phosphorylation of this site in ILK1 has apparently not been reported from high throughput mass spectrometry studies recorded in PhosphoSitePlus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.3 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very weak immunoreactivity of a target-sized protein by Western blotting in A549 cells. Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus macaque | Dog | Rat | Frog | Zebra fish.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 50-55 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in A549 and MCF7 cells. A maturation-induced ~75 kDa cross-reactive protein was detected in germinal vesicle-positive maturing sea star oocytes.
Related Product 1: ILK (348-354) pY351 antibody blocking peptide (Cat. No.: PE-04ABW85)
Related Product 2: ILK1-pS343 phosphosite-specific antibody (Cat. No.: AB-PK661)
Scientific Background: ILK (ILK1) is a protein-serine/threonine kinase of the TKL group and MLK family. It features an N-terminal domain with five ankyrin repeats (binding PINCH), a central Pleckstrin Homology (PH)-like domain (binding PtdIns(3,4,5)P3), and a C-terminal catalytic domain (binding beta-integrins, parvins, and paxillin). ILK is typically found in focal adhesions and the cytosol, but can also localize to centrosomes. It plays a critical role in the regulation of integrin-mediated signal transduction. It acts as a scaffold protein, linking integrins to the cytoskeleton, and is indispensable for the function of tissues like muscle, heart, and skin. ILK is a core component of the heterotrimeric ILK–PINCH–parvin (IPP) complex, which connects integrins to F-actin, facilitating cell adhesion, migration, and force generation. It is stimulated rapidly but transiently by both cell fibronectin interactions, as well as by insulin, in a PI3K-dependent manner, likely via the binding of PtdIns(3,4,5)P3. It is a component of the complex ILK-PINCH, which is thought to be a primary point for the convergence of integrin- and growth-factor signalling as well as a regulator of cell architecture, integrin-mediated adhesion, and anchorage-dependent cell growth in epithelial cells. Downstream targets of ILK include the beta-1 and beta-3 integrin subunits as well as Akt1 (at Ser-473) and GSK3b. The ILK mutation, H99D can modulate interactions with LIMS1. An E359K mutation can inactivate ILK. Mutations or dysfunction in the ILK gene are linked to cardiac diseases due to its role in maintaining muscle cell adhesion and architecture. ILK appears to be a oncoprotein (OP), but its relatively low rate of mutation in human cancers supports its assignment as a tumour requiring protein (TRP). It has been implicated as an oncoprotein due to its ability to activate Akt isoforms, although it has weak phosphotransferase activity that can be stimulated in vitro with manganese. Overexpression of ILK is correlated with promoting epithelial-mesenchymal transition (EMT), tumour metastasis, and invasion. This description may include information annotated by UniProt and/or Google AI.